Breaking News Instant updates and real-time market news.

ACER

Acer Therapeutics

$25.75

-1.08 (-4.03%)

08:41
04/16/19
04/16
08:41
04/16/19
08:41

Acer Therapeutics announces publication of long-term vEDS patient registry data

Acer Therapeutics announced the publication of long-term data from a cohort of COL3A1-positive Vascular Ehlers-Danlos Syndrome, or vEDS, patients in the Journal of the American College of Cardiology, or JACC. This published study describes outcomes in 144 COL3A1-positive vEDS patients clinically monitored and treated at the French National Referral Center for Rare Vascular Diseases between the years 2000 and 2017. Patients were followed for a median of 5.3 years, and up to 20 years. At the initial work up, 50% of patients were not treated regularly and only 33.3% were taking celiprolol; by the end of the study period, the majority were treated with celiprolol alone or in combination with other medications. Once the maximum tolerated dose of celiprolol was reached, 90 patients remained at this dose throughout their follow-up. Only 5 patients required dose reduction due to fatigue, and no serious drug-related adverse event was recorded. Patients had a lower mortality rate than that expected from the natural history of the disease as described in previous U.S. reports. Survival curve analysis showed that those not treated with celiprolol had a significantly worse outcome than celiprolol-treated patients: survival was 80.7% in those treated with celiprolol versus 48.5% in those not treated after 11.1 years of follow-up. Survival was significantly higher in patients treated with a median dose of celiprolol of 400mg/day vs. patients treated with a lower median dose of 217mg/d, suggesting a dose effect and that 400mg/day should be considered the optimal dose. The authors also observed a relative decrease in hospitalization rates for acute arterial events during the time period in which the majority of patients were on celiprolol, suggesting a positive effect of celiprolol on the incidence and/or severity of new arterial events. The authors concluded that in this large, long-term cohort study, vEDS patients had a higher survival rate than expected relative to the known natural history of the disease and a lower annual occurrence of arterial complications, and that celiprolol use was potentially associated with these significant improvements in clinical outcomes.

  • 05

    Jun

  • 25

    Jun

ACER Acer Therapeutics
$25.75

-1.08 (-4.03%)

08/17/18
RAJA
08/17/18
UPGRADE
Target $46
RAJA
Strong Buy
Acer Therapeutics upgraded to Strong Buy on ACER-100 estimates at Raymond James
Raymond James analyst Laura Chico upgraded Acer Therapeutics to Strong Buy from Outperform and increased its price target to $46 from $31 after speakings with industry contacts and management. Chico is incrementally more positive on the ACER-001 and overall company story and raised ACER-100 estimates to reflect slightly higher share gains and probability of success assumptions.
12/20/18
NEED
12/20/18
INITIATION
Target $48
NEED
Buy
Acer Therapeutics initiated with a Buy at Needham
Needham analyst Serge Belanger initiated Acer Therapeutics with a Buy rating and a price target of $48. The analyst sees the company as an "attractive under-the-radar orphan drug story with two late-stage derisked assets that have key transformational catalysts in 2019." Belanger cites Acer's lead product candidate currently under FDA review for the treatment of vascular Ehlers-Danlose syndrome that affects up to 5K people in the U.S. along with its ACER-001 drug candidate that is currently under development for Urea Cycle Disorders and on track for an NDA filing in late-2019.
12/20/18
12/20/18
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. PolarityTE (PTE) initiated with an Overweight at Piper Jaffray. 2. Acer Therapeutics (ACER) initiated with a Buy at Needham. 3. Jagged Peak Energy (JAG) initiated with a Neutral at Macquarie and a Sector Weight at KeyBanc. 4. Inspired Entertainment (INSE) initiated with a Buy at Roth Capital. 5. HD Supply (HDS) initiated with a Buy at Buckingham. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/15/19
RAJA
02/15/19
INITIATION
Target $40
RAJA
Outperform
Acer Therapeutics reinstated with an Outperform at Raymond James
Raymond James reinstated Acer Therapeutics with an Outperform and $40 price target.

TODAY'S FREE FLY STORIES

WMT

Walmart

$103.51

0.45 (0.44%)

06:50
04/25/19
04/25
06:50
04/25/19
06:50
Periodicals
Walmart to evaluate options for Asda including IPO, Bloomberg reports »

Walmart is reviewing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 06

    May

  • 16

    May

  • 29

    May

  • 05

    Jun

  • 07

    Jun

  • 13

    Nov

AERI

Aerie Pharmaceuticals

$38.85

-0.64 (-1.62%)

06:49
04/25/19
04/25
06:49
04/25/19
06:49
Hot Stocks
Aerie Pharmaceuticals: NDA for AR-13503 accepted by FDA »

Aerie Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 23

    May

LLY

Eli Lilly

$117.99

0.48 (0.41%)

06:49
04/25/19
04/25
06:49
04/25/19
06:49
Hot Stocks
Eli Lilly facilitating withdrawal of Lartruvo after ANNOUNCE trial failure »

Eli Lilly announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    Apr

  • 04

    May

  • 06

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 18

    May

NVT

nVent Electric

$28.40

0.19 (0.67%)

06:49
04/25/19
04/25
06:49
04/25/19
06:49
Earnings
nVent Electric still sees 2019 adjusted EPS $1.80-$1.90, consensus $1.87 »

Still sees 2019 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

FAF

First American

$56.18

0.17 (0.30%)

06:48
04/25/19
04/25
06:48
04/25/19
06:48
Earnings
First American reports Q1 EPS 74c, consensus 68c »

Reports Q1 revenue $1.3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 07

    May

  • 13

    Nov

NVT

nVent Electric

$28.40

0.19 (0.67%)

06:47
04/25/19
04/25
06:47
04/25/19
06:47
Earnings
nVent Electric reports Q1 adjusted EPS 39c , consensus 39c »

Reports Q1 revenue $538M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

ENB

Enbridge

06:45
04/25/19
04/25
06:45
04/25/19
06:45
Downgrade
Enbridge rating change  »

Enbridge downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

GBNXF

Gibson Energy

06:45
04/25/19
04/25
06:45
04/25/19
06:45
Downgrade
Gibson Energy rating change  »

Gibson Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LAD

Lithia Motors

$104.90

7.19 (7.36%)

06:45
04/25/19
04/25
06:45
04/25/19
06:45
Upgrade
Lithia Motors rating change  »

Stephens upgrades Lithia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 28

    May

  • 13

    Nov

BBU

Brookfield Business Partners

$37.80

-0.17 (-0.45%)

06:45
04/25/19
04/25
06:45
04/25/19
06:45
Hot Stocks
Brookfield Business Partners selling BGRS for $230M in proceeds »

Brookfield Business…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

CBZ

CBIZ

$20.59

-0.005 (-0.02%)

06:44
04/25/19
04/25
06:44
04/25/19
06:44
Earnings
CBIZ backs FY19 EPS view up 10%-12%, consensus $1.20 »

Backs FY19 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 06

    Aug

NGD

New Gold

$0.88

0.0253 (2.96%)

06:42
04/25/19
04/25
06:42
04/25/19
06:42
Earnings
New Gold reports Q1 adjusted EPS 0c, consensus 1c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

MTSI

Macom

$15.86

-0.33 (-2.04%)

06:42
04/25/19
04/25
06:42
04/25/19
06:42
Downgrade
Macom rating change  »

Macom downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

CBZ

CBIZ

$20.59

-0.005 (-0.02%)

06:42
04/25/19
04/25
06:42
04/25/19
06:42
Earnings
CBIZ reports Q1 EPS 67c, consensus 70c »

Reports Q1 revenue $270M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 06

    Aug

BIP

Brookfield Infrastructure

$41.62

-0.03 (-0.07%)

06:42
04/25/19
04/25
06:42
04/25/19
06:42
Downgrade
Brookfield Infrastructure rating change  »

Brookfield Infrastructure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

WYNN

Wynn Resorts

$144.35

1.35 (0.94%)

06:42
04/25/19
04/25
06:42
04/25/19
06:42
Upgrade
Wynn Resorts rating change  »

Wynn Resorts upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

ALXN

Alexion

$130.12

-2.24 (-1.69%)

06:41
04/25/19
04/25
06:41
04/25/19
06:41
Earnings
Alexion raises FY19 adj. EPS view to $9.25-$9.45 from $9.10-$9.30 »

FY19 consensus $9.31.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

  • 06

    May

  • 14

    May

  • 28

    Jun

LUV

Southwest

$52.92

0.11 (0.21%)

06:40
04/25/19
04/25
06:40
04/25/19
06:40
Earnings
Southwest reports Q1 EPS 70c, consensus 61c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 15

    May

  • 21

    May

  • 13

    Nov

MMM

3M

$219.24

-0.28 (-0.13%)

06:39
04/25/19
04/25
06:39
04/25/19
06:39
Hot Stocks
Breaking Hot Stocks news story on 3M »

3M drops 6% to $205.00…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 14

    May

  • 18

    May

  • 29

    May

EQT

EQT Corporation

$20.75

-0.26 (-1.24%)

06:39
04/25/19
04/25
06:39
04/25/19
06:39
Earnings
EQT Corporation reports Q1 adjusted EPS 83c, consensus 74c »

Reports Q1 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

ALXN

Alexion

$130.12

-2.24 (-1.69%)

06:38
04/25/19
04/25
06:38
04/25/19
06:38
Earnings
Alexion reports Q1 adjusted EPS $2.39, consensus $2.19 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

  • 06

    May

  • 14

    May

  • 28

    Jun

BWA

BorgWarner

$43.50

-0.135 (-0.31%)

06:38
04/25/19
04/25
06:38
04/25/19
06:38
Earnings
BorgWarner backs FY19 EPS view $4.00-$4.35, consensus $4.20 »

Backs FY19 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

SSNLF

Samsung

$0.00

(0.00%)

, BTC

Bitcoin

$0.00

(0.00%)

06:37
04/25/19
04/25
06:37
04/25/19
06:37
Periodicals
Samsung plans to develop its own Ethereum-based blockchain, token, TNW reports »

Samsung is planning to…

SSNLF

Samsung

$0.00

(0.00%)

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLO

Valero

$87.75

-2.53 (-2.80%)

06:36
04/25/19
04/25
06:36
04/25/19
06:36
Hot Stocks
Valero says expects to invests about $2.5B of capital in 2019, 2020 »

The Houston alkylation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    Apr

BWA

BorgWarner

$43.50

-0.135 (-0.31%)

06:36
04/25/19
04/25
06:36
04/25/19
06:36
Earnings
BorgWarner sees Q2 adj. EPS 99c-$1.05, consensus $1.07 »

Sees Q2 organic sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.